Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-04-03 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于非公开发行股票申请获得中国证监会受理的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (477 characters) regarding the acceptance by the China Securities Regulatory Commission (CSRC) of the company's application for a non-public issuance of new shares. It states that the application has been accepted for review but is still subject to approval. There is no detailed financial data or report content, only a regulatory update on the financing process. This fits the definition of a Capital/Financing Update (CAP) rather than a full report or regulatory filing. The document is not a report publication announcement or certification, but a financing activity update.
2020-04-03 Chinese
关于股东股份质押变动的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding changes in the pledge status of shares held by a shareholder (Zhejiang Jihe Venture Capital Co., Ltd.) in Betta Pharmaceuticals Co., Ltd. It details the number of shares pledged, the proportion of total shares, pledge start and end dates, and the pledgee. The document is short (1579 characters) and focuses solely on share pledge changes without financial statements or broader company performance data. This fits the category of a Major Shareholding Notification, which covers notifications of changes in significant share ownership or related share transactions such as pledges. It is not an annual or interim report, nor an earnings release or management report. It is not a regulatory filing or report publication announcement because it contains substantive information about share pledge changes. Therefore, the correct classification is Major Shareholding Notification (MRQ).
2020-03-25 Chinese
关于股东股份质押变动的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding changes in shareholder stock pledges, including details about pledge releases, extensions, and cumulative pledge status. It includes tables with shareholder names, pledge quantities, dates, and pledgees. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledge changes, which fits the category of a Regulatory Filing (RNS) as it does not match other more specific categories like Capital/Financing Update or Major Shareholding Notification since it focuses on pledge status rather than share ownership changes or capital raising.
2020-03-19 Chinese
2020年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2020 first extraordinary general meeting of shareholders of Betta Pharmaceuticals Co., Ltd. It includes voting results on various proposals related to a non-public issuance of shares, the use of raised funds, and shareholder return plans. The text contains detailed voting statistics, meeting attendance, and legal opinions confirming the validity of the meeting and resolutions. This is not a full report like an annual or interim report, nor is it a presentation or earnings release. It is a formal announcement of the voting results from a shareholders' meeting. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support a high confidence in this classification.
2020-03-19 Chinese
2020年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance qualifications, agenda, and voting results of a company's 2020 first extraordinary general meeting (临时股东大会). It details the legality and validity of the meeting and voting process, including the results of votes on various proposals related to a non-public stock issuance. The document is not a financial report, earnings release, or management discussion, but a legal opinion on the shareholder meeting and its resolutions. This type of document corresponds to Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of a shareholder meeting. The document length is over 10,000 characters and contains detailed voting results, not just an announcement of a report publication or a brief notice. Therefore, the correct classification is DVA with high confidence.
2020-03-19 Chinese
关于召开2020年第一次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2020 first extraordinary general meeting (临时股东大会) of Betta Pharmaceuticals Co., Ltd. It includes information about the meeting date, voting methods (onsite and online), agenda items for shareholder approval, registration procedures, and voting instructions. The content focuses on notifying shareholders about the meeting and the proposals to be voted on, including non-public stock issuance plans and related financial proposals. There are no financial statements, earnings data, or management discussion and analysis present. The document is not a report itself but an announcement about the meeting and its agenda, which is typical of a Proxy Solicitation & Information Statement or a meeting notice. Given the detailed voting instructions and proposal descriptions, it aligns best with the Proxy Solicitation & Information Statement (PSI) category rather than a simple meeting notice (which would be shorter) or a voting results announcement (which would come after the meeting).
2020-03-17 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.